Clinical Trial Update: Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific [Phase 2]

View source ↗

Summary

Phase II single-arm trial of AZD9291 (osimertinib) for non-small cell lung cancer patients in the Asia-Pacific region has completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-04-25